BCIQ Profiles

Company Profile Report

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a

Read the full 240 word article

How to gain access

Continue reading with a
two-week free trial.